Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Advanced Non-small Cell Lung Cancer 1

Interventions

Pemetrexed 23Carboplatin 21Cisplatin 20pembrolizumab 15Docetaxel 14Paclitaxel 10Gemcitabine 8Drug Therapy 7Bevacizumab 7Gefitinib 5Radiotherapy 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4130-nm albumin-bound paclitaxel 4cemiplimab 3atezolizumab 3anlotinib 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cobimetinib 2auricularum 2aumolertinib 2apatinib 2Vemurafenib 2Topotecan 2Temozolomide 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × rofecoxib × Thoracic × Clear all
NCT00385606 2023-03-23

Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC

National Cancer Institute, Naples

Phase 2/3 Completed
400 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡